Antibody fusions with immunomodulatory proteins for cancer therapy

Pharmacology and Therapeutics

Volumn 154, Issue , 2015, Pages 57-66

  Müller, Dafne ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

Antibody cytokine fusion proteins; Immunocytokines; Targeted cancer immunotherapy

Indexed keywords

ANTIBODY; COLONY STIMULATING FACTOR; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOCYTOKINE; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; INTERLEUKIN DERIVATIVE; AUTACOID; CYTOKINE; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY ENGINEERING; ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CANCER THERAPY; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN TARGETING; REVIEW; TUMOR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; NATURAL KILLER CELL; NEOPLASMS; PROCEDURES;

ANTIBODIES, MONOCLONAL; CYTOKINES; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; INFLAMMATION MEDIATORS; KILLER CELLS, NATURAL; NEOPLASMS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84941422358     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.07.001     Document Type: Review

References (124)

1. P.A. Ascierto, F.M. Marincola, and A. Ribas Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application J Transl Med 9 2011 196
2. R. Baluna, J. Rizo, B.E. Gordon, V. Ghetie, and E.S. Vitetta Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome Proc Natl Acad Sci U S A 96 7 1999 3957 3962
3. E. Balza, B. Carnemolla, L. Mortara, P. Castellani, D. Soncini, R.S. Accolla, and et al. Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha Int J Cancer 127 1 2010 101 110
4. R.A. Beckman, L.M. Weiner, and H.M. Davis Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors Cancer 109 2 2007 170 179
5. F. Belardelli, and M. Ferrantini Cytokines as a link between innate and adaptive antitumor immunity Trends Immunol 23 4 2002 201 208
6. A. Bessard, V. Solé, G. Bouchaud, A. Quéméner, and Y. Jacques High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer Mol Cancer Ther 8 9 2009 2736 2745
7. L. Borsi, E. Balza, B. Carnemolla, F. Sassi, P. Castellani, A. Berndt, and et al. Selective targeted delivery of TNFalpha to tumor blood vessels Blood 102 13 2003 4384 4392
8. O. Boyman, and J. Sprent The role of interleukin-2 during homeostasis and activation of the immune system Nat Rev Immunol 12 3 2012 180 190
9. E. Bremer Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy ISRN Oncol 2013 2013 371854
10. P. Carter Improving the efficacy of antibody-based cancer therapies Nat Rev Cancer 1 2 2001 118 129
11. E.F. Castillo, and K.S. Schluns Regulating the immune system via IL-15 transpresentation Cytokine 59 3 2012 479 490
12. S. Ceeraz, E.C. Nowak, and R.J. Noelle B7 family checkpoint regulators in immune regulation and disease Trends Immunol 34 11 2013 556 563
13. L. Chen, and D.B. Flies Molecular mechanisms of T cell co-stimulation and co-inhibition Nat Rev Immunol 13 4 2013 227 242
14. M. Croft The role of TNF superfamily members in T-cell function and diseases Nat Rev Immunol 9 4 2009 271 285
15. M. Croft, C.A. Benedict, and C.F. Ware Clinical targeting of the TNF and TNFR superfamilies Nat Rev Drug Discov 12 2 2013 147 168
16. R. Danielli, R. Patuzzo, P.A. Ruffini, A. Maurichi, L. Giovannoni, G. Elia, and et al. Armed antibodies for cancer treatment: A promising tool in a changing era Cancer Immunol Immunother 64 1 2015 113 121
17. J.H. De Wilt, T.L. ten Hagen, G. de Boeck, S.T. van Tiel, E.A. de Bruijn, and A.M. Eggermont Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion Br J Cancer 82 5 2000 1000 1003
18. M. Del Vecchio, E. Bajetta, S. Canova, M.T. Lotze, A. Wesa, G. Parmiani, and et al. Interleukin-12: Biological properties and clinical application Clin Cancer Res 13 16 2007 4677 4685
19. C.S. Dolman, B.M. Mueller, H.N. Lode, R. Xiang, S.D. Gillies, and R.A. Reisfeld Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy Clin Cancer Res 4 10 1998 2551 2557
20. G. Driessens, J. Kline, and T.F. Gajewski Costimulatory and coinhibitory receptors in anti-tumor immunity Immunol Rev 229 1 2009 126 144
21. S. Dubois, H.J. Patel, M. Zhang, T.A. Waldmann, and J.R. Müller Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action J Immunol 180 4 2008 2099 2106
22. C. Ebbinghaus, R. Ronca, M. Kaspar, D. Grabulovski, A. Berndt, H. Kosmehl, and et al. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy Int J Cancer 116 2 2005 304 313
23. T.K. Eigentler, B. Weide, F. de Braud, G. Spitaleri, A. Romanini, A. Pflugfelder, and et al. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma Clin Cancer Res 17 24 2011 7732 7742
24. A.L. Epstein, M.M. Mizokami, J. Li, P. Hu, and L.A. Khawli Identification of a protein fragment of interleukin 2 responsible for vasopermeability J Natl Cancer Inst 95 10 2003 741 749
25. M. Ferrantini, I. Capone, and F. Belardelli Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use Biochimie 89 6-7 2007 884 893
26. S. Folli, A. Pèlegrin, Y. Chalandon, X. Yao, F. Buchegger, D. Lienard, and et al. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability Int J Cancer 53 5 1993 829 836
27. K. Frey, A. Zivanovic, K. Schwager, and D. Neri Antibody-based targeting of interferon-alpha to the tumor neovasculature: A critical evaluation Integr Biol (Camb) 3 4 2011 468 478
28. V. Gafner, E. Trachsel, and D. Neri An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties Int J Cancer 119 9 2006 2205 2212
29. L. Galluzzi, E. Vacchelli, W.H. Fridman, J. Galon, C. Sautès-Fridman, E. Tartour, and et al. Trial Watch: Monoclonal antibodies in cancer therapy OncoImmunology 1 1 2012 28 37
30. G. Garcin, F. Paul, M. Staufenbiel, Y. Bordat, J. Van der Heyden, S. Wilmes, and et al. High efficiency cell-specific targeting of cytokine activity Nat Commun 5 2014 3016
31. S. Gillessen, U.S. Gnad-Vogt, E. Gallerani, J. Beck, C. Sessa, A. Omlin, and et al. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours Eur J Cancer 49 1 2013 35 44
32. S.D. Gillies, Y. Lan, T. Hettmann, B. Brunkhorst, Y. Sun, S.O. Mueller, and et al. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity Clin Cancer Res 17 11 2011 3673 3685
33. S.D. Gillies, Y. Lan, K.M. Lo, M. Super, and J. Wesolowski Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors Cancer Res 59 9 1999 2159 2166
34. S.D. Gillies, K.M. Lo, C. Burger, Y. Lan, T. Dahl, and W.K. Wong Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis Clin Cancer Res 8 1 2002 210 216
35. S.D. Gillies, D. Young, K.M. Lo, and S. Roberts Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins Bioconjug Chem 4 3 1993 230 235
36. G. Graziani, L. Tentori, and P. Navarra Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer Pharmacol Res 65 1 2012 9 22
37. J.A. Gubbels, B. Gadbaw, I.N. Buhtoiarov, S. Horibata, A.K. Kapur, D. Patel, and et al. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface Cancer Immunol Immunother 60 12 2011 1789 1800
38. R. Gupta, and L.A. Emens GM-CSF-secreting vaccines for solid tumors: Moving forward Discov Med 10 50 2010 52 60
39. D.W. Gutkin, and M.R. Shurin Clinical evaluation of systemic and local immune responses in cancer: Time for integration Cancer Immunol Immunother 63 1 2013 45 57
40. C. Halin, V. Gafner, M.E. Villani, L. Borsi, A. Berndt, H. Kosmehl, and et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha Cancer Res 63 12 2003 3202 3210
41. J.A. Hank, J.E. Surfus, J. Gan, P. Jaeger, S.D. Gillies, R.A. Reisfeld, and et al. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2) Clin Cancer Res 2 12 1996 1951 1959
42. T. Hemmerle, C. Hess, D. Venetz, and D. Neri Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily J Biotechnol 172 2014 73 76
43. T. Hemmerle, and D. Neri The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo Cancer Immunol Res 2 6 2014 559 567
44. T. Hemmerle, and D. Neri The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer Int J Cancer 134 2 2014 467 477
45. T. Hemmerle, P. Probst, L. Giovannoni, A.J. Green, T. Meyer, and D. Neri The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity Br J Cancer 109 5 2013 1206 1213
46. P. Holliger, O. Manzke, M. Span, R. Hawkins, B. Fleischmann, L. Qinghua, and et al. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 × anti-CEA bispecific diabodies and B7 × anti-CEA bispecific fusion proteins Cancer Res 59 12 1999 2909 2916
47. J.L. Hornick, L.A. Khawli, P. Hu, J. Sharifi, C. Khanna, and A.L. Epstein Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors Clin Cancer Res 5 1 1999 51 60
48. N. Hornig, V. Kermer, K. Frey, P. Diebolder, R.E. Kontermann, and D. Müller Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy J Immunother 35 5 2012 418 429
49. N. Hornig, K. Reinhardt, V. Kermer, R.E. Kontermann, and D. Müller Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy Cancer Immunol Immunother 62 8 2013 1369 1380
50. P. Hu, M. Mizokami, G. Ruoff, L.A. Khawli, and A.L. Epstein Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity Blood 101 12 2003 4853 4861
51. T.H. Huang, K.R. Chintalacharuvu, and S.L. Morrison Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities J Immunol 179 10 2007 6881 6888
52. M. Jakobisiak, J. Golab, and W. Lasek Interleukin 15 as a promising candidate for tumor immunotherapy Cytokine Growth Factor Rev 22 2 2011 99 108
53. E.E. Johnson, H.D. Lum, A.L. Rakhmilevich, B.E. Schmidt, M. Furlong, I.N. Buhtoiarov, and et al. Intratumoral immunocytokine treatment results in enhanced antitumor effects Cancer Immunol Immunother 57 12 2008 1891 1902
54. I.S. Junttila, R.J. Creusot, I. Moraga, D.L. Bates, M.T. Wong, M.N. Alonso, and et al. Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines Nat Chem Biol 8 12 2012 990 998
55. M. Kaspar, E. Trachsel, and D. Neri The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis Cancer Res 67 10 2007 4940 4948
56. V. Kermer, V. Baum, N. Hornig, R.E. Kontermann, and D. Müller An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site Mol Cancer Ther 11 6 2012 1279 1288
57. M.H. Kershaw, J.A. Westwood, and P.K. Darcy Gene-engineered T cells for cancer therapy Nat Rev Cancer 13 8 2013 525 541
58. C. Klein, I. Waldhauer, V. Nicolini, C. Dunn, A. Freimoser-Grundschober, S. Herter, and et al. Novel tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for immunotherapy of cancer. ASH, 2013, poster #2278 Blood 122 21 2013 2278-2278
59. R.E. Kontermann Antibody-cytokine fusion proteins Arch Biochem Biophys 526 2 2012 194 205
60. C. Kyi, and M.A. Postow Checkpoint blocking antibodies in cancer immunotherapy FEBS Lett 588 2 2014 368 376
61. W. Lasek, R. Zagożdżon, and M. Jakobisiak Interleukin 12: Still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 63 5 2014 419 435
62. J. Laurent, C. Touvrey, S. Gillessen, M. Joffraud, M. Vicari, C. Bertrand, and et al. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein J Transl Med 11 2013 5
63. M.G. Lechner, S.M. Russell, R.S. Bass, and A.L. Epstein Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors Immunotherapy 3 11 2011 1317 1340
64. A.M. Levin, D.L. Bates, A.M. Ring, C. Krieg, J.T. Lin, L. Su, and et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine' Nature 484 7395 2012 529 533
65. W. Liao, J.X. Lin, and W.J. Leonard Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy Immunity 38 1 2013 13 25
66. T. List, and D. Neri Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site MAbs 4 6 2012 775 783
67. T. List, and D. Neri Immunocytokines: A review of molecules in clinical development for cancer therapy Clin Pharmacol 5 2013 29 45
68. A. Liu, P. Hu, L.A. Khawli, and A.L. Epstein B7.1/NHS76: A new costimulator fusion protein for the immunotherapy of solid tumors J Immunother 29 4 2006 425 435
69. C.L. Mackall, T.J. Fry, and R.E. Gress Harnessing the biology of IL-7 for therapeutic application Nat Rev Immunol 11 5 2011 330 342
70. J. Marks-Konczalik, S. Dubois, J.M. Losi, H. Sabzevari, N. Yamada, L. Feigenbaum, and et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice Proc Natl Acad Sci U S A 97 2000 11445 11450
71. J. Mårlind, M. Kaspar, E. Trachsel, R. Sommavilla, S. Hindle, C. Bacci, and et al. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy Clin Cancer Res 14 20 2008 6515 6524
72. R. Meazza, B. Azzarone, A.M. Orengo, and S. Ferrini Role of common-gamma chain cytokines in NK cell development and function: Perspectives for immunotherapy J Biomed Biotechnol 2011 2011 861920
73. I. Melero, A.M. Grimaldi, J.L. Perez-Gracia, and P.A. Ascierto Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination Clin Cancer Res 19 5 2013 997 1008
74. A.E. Moran, M. Kovacsovics-Bankowski, and A.D. Weinberg The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy Curr Opin Immunol 25 2 2013 230 237
75. M. Moschetta, F. Pretto, A. Berndt, K. Galler, P. Richter, A. Bassi, and et al. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts Cancer Res 72 7 2012 1814 1824
76. D. Müller Antibody-cytokine fusion proteins for cancer immunotherapy: An update on recent developments BioDrugs 28 2 2014 123 131
77. D. Müller, K. Frey, and R.E. Kontermann A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy J Immunother 31 8 2008 714 722
78. D. Müller, and R.E. Kontermann Bispecific antibodies for cancer immunotherapy: Current perspectives BioDrugs 24 2 2010 89 98
79. N. Müller, A. Wyzgol, S. Münkel, K. Pfizenmaier, and H. Wajant Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization FEBS J 275 9 2008 2296 2304
80. V. Nicolini, I. Waldhauer, A. Freimoser-Grundschober, S. Colombetti, F. Cavallo, M. Bacac, and et al. Combination with the novel tumor-targeted CEA-IL2v immunocytokine enhances the activity of ADCC competent and glycoengineered antibodies in vitro and in vivo. poster, AACR annual meeting, April 5-9, San Diego, USA, Permanent Abstract Number: 2579 Cancer Res 74 19 Supplement 2014 2579-2579
81. W.W. Overwijk, and K.S. Schluns Functions of γC cytokines in immune homeostasis: Current and potential clinical applications Clin Immunol 132 2 2009 153 165
82. F. Papadia, V. Basso, R. Patuzzo, A. Maurichi, A. Di Florio, L. Zardi, and et al. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma J Surg Oncol 107 2 2012 173 179
83. A.D. Pardee, A.K. Wesa, and W.J. Storkus Integrating costimulatory agonists to optimize immune-based cancer therapies Immunotherapy 1 2 2009 249 264
84. N. Pasche, and D. Neri Immunocytokines: A novel class of potent armed antibodies Drug Discov Today 17 11-12 2012 583 590
85. N. Pasche, J. Woytschak, S. Wulhfard, A. Villa, K. Frey, and D. Neri Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7 J Biotechnol 154 1 2011 84 92
86. N. Pasche, S. Wulhfard, F. Pretto, E. Carugati, and D. Neri The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel Clin Cancer Res 18 15 2012 4092 4103
87. M. Pedretti, C. Verpelli, J. Mårlind, G. Bertani, C. Sala, D. Neri, and et al. Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma Br J Cancer 103 6 2010 827 836
88. G.K. Philips, and M. Atkins Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies Int Immunol 27 1 2015 39 46
89. F. Pretto, G. Elia, N. Castioni, and D. Neri Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy Cancer Immunol Immunother 63 9 2014 901 910
90. C. Rathi, and B. Meibohm Clinical pharmacology of bispecific antibody constructs J Clin Pharmacol 55 Suppl. 3 2015 S21 S28
91. A. Robinson-Mosher, J.H. Chen, J. Way, and P.A. Silver Designing cell-targeted therapeutic proteins reveals the interplay between domain connectivity and cell binding Biophys J 107 10 2014 2456 2466
92. R.E. Sadun, W.E. Hsu, N. Zhang, Y.C. Nien, S.A. Bergfeld, H. Sabzevari, and et al. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models J Immunother 31 3 2008 235 245
93. R.H. Schabowsky, K.G. Elpek, S. Madireddi, R.K. Sharma, E.S. Yolcu, L. Bandura-Morgan, and et al. A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity Vaccine 28 2 2009 512 522
94. D.A. Schaer, J.T. Murphy, and J.D. Wolchok Modulation of GITR for cancer immunotherapy Curr Opin Immunol 24 2 2012 217 224
95. K. Schwager, T. Hemmerle, D. Aebischer, and D. Neri The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF J Invest Dermatol 133 3 2013 751 758
96. R.B. Sims Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer Vaccine 30 29 2012 4394 4397
97. P.M. Sondel, and S.D. Gillies Current and potential uses of immunocytokines as cancer immunotherapy Antibodies (Basel) 1 2 2012 149 171
98. G. Spitaleri, R. Berardi, C. Pierantoni, T. De Pas, C. Noberasco, C. Libbra, and et al. Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours J Cancer Res Clin Oncol 139 3 2013 447 455
99. R. Spolski, and W.J. Leonard Interleukin-21: Basic biology and implications for cancer and autoimmunity Annu Rev Immunol 26 2008 57 79
100. R. Stebbings, S. Poole, and R. Thorpe Safety of biologics, lessons learnt from TGN1412 Curr Opin Biotechnol 20 6 2009 673 677
101. J.C. Steel, T.A. Waldmann, and J.C. Morris Interleukin-15 biology and its therapeutic implications in cancer Trends Pharmacol Sci 33 1 2012 35 41
102. T.A. Stoklasek, K.S. Schluns, and L. Lefrançois Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo J Immunol 177 9 2006 6072 6080
103. S.W. Stonier, and K.S. Schluns Trans-presentation: A novel mechanism regulating IL-15 delivery and responses Immunol Lett 127 2 2010 85 92
104. S.\L. Topalian, C.G. Drake, and D.M. Pardoll Immune checkpoint blockade: A common denominator approach to cancer therapy Cancer Cell 27 4 2015 450 461
105. A. Tzeng, B.H. Kwan, C.F. Opel, T. Navaratna, and K.D. Wittrup Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution Proc Natl Acad Sci U S A 112 11 2015 3320 3325
106. E. Vacchelli, F. Aranda, F. Obrist, A. Eggermont, J. Galon, I. Cremer, and et al. Trial watch: Immunostimulatory cytokines in cancer therapy OncoImmunology 3 2014 e29030
107. E. Vacchelli, L. Galluzzi, A. Eggermont, J. Galon, E. Tartour, L. Zitvogel, and et al. Trial Watch: Immunostimulatory cytokines OncoImmunology 1 4 2012 493 506
108. M.M. Van den Heuvel, M. Verheij, R. Boshuizen, J. Belderbos, A.M. Dingemans, D. De Ruysscher, and et al. NHS-IL2 combined with radiotherapy: Preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy J Transl Med 13 1 2015 32
109. M.D. Vesely, M.H. Kershaw, R.D. Schreiber, and M.J. Smyth Natural innate and adaptive immunity to cancer Annu Rev Immunol 29 2011 235 271
110. M. Vincent, A. Bessard, D. Cochonneau, G. Teppaz, V. Solé, M. Maillasson, and et al. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency Int J Cancer 133 3 2013 757 765
111. M. Vincent, G. Teppaz, L. Lajoie, V. Solé, A. Bessard, M. Maillasson, and et al. Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse MAbs 6 4 2014 1026 1037
112. P. Votavova, J. Tomala, and M. Kovar Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera Immunol Lett 159 1-2 2014 1 10
113. H. Wajant, J. Gerspach, and K. Pfizenmaier Engineering death receptor ligands for cancer therapy Cancer Lett 332 2 2013 163 174
114. T. Waldmann The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: Implications for the immunotherapy of rheumatological diseases Arthritis Res 4 Suppl. 3 2002 S161 S167
115. T.A. Waldmann, E. Lugli, M. Roederer, L.P. Perera, J.V. Smedley, R.P. Macallister, and et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques Blood 117 18 2001 4787 4795
116. B. Weide, T.K. Eigentler, A. Pflugfelder, H. Zelba, A. Martens, G. Pawelec, and et al. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses Cancer Immunol Res 2 7 2014 668 678
117. A. Wyzgol, N. Müller, A. Fick, S. Munkel, G.U. Grigoleit, K. Pfizenmaier, and et al. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand J Immunol 183 3 2009 1851 1861
118. W. Xu, M. Jones, B. Liu, X. Zhu, C.B. Johnson, A.C. Edwards, and et al. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: Interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma Cancer Res 73 10 2013 3075 3086
119. C. Xuan, K.K. Steward, J.M. Timmerman, and S.L. Morrison Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma Blood 115 14 2010 2864 2871
120. R.K. Yang, N.A. Kalogriopoulos, A.L. Rakhmilevich, E.A. Ranheim, S. Seo, K. Kim, and et al. Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention J Immunol 189 5 2012 2656 2664
121. R.K. Yang, N.A. Kalogriopoulos, A.L. Rakhmilevich, E.A. Ranheim, S. Seo, K. Kim, and et al. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival Cancer Immunol Immunother 62 8 2013 1303 1313
122. C.M. Zegers, N.H. Rekers, D.H. Quaden, N.G. Lieuwes, A. Yaromina, W.T. Germeraad, and et al. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects Clin Cancer Res 21 5 2015 1151 1160
123. N. Zhang, R.E. Sadun, R.S. Arias, M.L. Flanagan, S.M. Sachsman, Y.C. Nien, and et al. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors Clin Cancer Res 13 9 2007 2758 2767
124. L. Zitvogel, L. Galluzzi, M.J. Smyth, and G. Kroemer Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance Immunity 39 1 2013 74 88